[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 19 of about 19
1. Straub RH, Härle P, Sarzi-Puttini P, Cutolo M: Tumor necrosis factor-neutralizing therapies improve altered hormone axes: an alternative mode of antiinflammatory action. Arthritis Rheum; 2006 Jul;54(7):2039-46
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor necrosis factor-neutralizing therapies improve altered hormone axes: an alternative mode of antiinflammatory action.
  • [MeSH-major] Antibodies / therapeutic use. Arthritis, Rheumatoid / drug therapy. Neurosecretory Systems / physiology. Tumor Necrosis Factor-alpha / antagonists & inhibitors. Tumor Necrosis Factor-alpha / physiology
  • [MeSH-minor] Adrenocorticotropic Hormone / physiology. Androgens / physiology. Autonomic Nervous System / physiology. Central Nervous System / physiology. Humans. Hydrocortisone / physiology. Hypothalamo-Hypophyseal System / physiology. Liver / physiology. Muscles / physiology. Pituitary-Adrenal System / physiology. Synovial Membrane / physiology

  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16802339.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Antibodies; 0 / Tumor Necrosis Factor-alpha; 9002-60-2 / Adrenocorticotropic Hormone; WI4X0X7BPJ / Hydrocortisone
  • [Number-of-references] 70
  •  go-up   go-down


2. Beck A, Jonas J, Frenzel H, Bähr R: [Gastrointestinal autonomic nerve tumor]. Zentralbl Chir; 2001 Sep;126(9):702-6
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastrointestinal autonomic nerve tumor].
  • Gastrointestinal autonomic nerve tumors (GAN-tumor) are rare malignant neurogenic stromal tumors of the intestinal tract.
  • The origin is suspected in the autonomic nerve plexus Meissner or Auerbach with the interstitial cells of Cajal as precursors.
  • We report on a 53-year-old patient with a clinical apparent and radiological 5 cm measuring tumor of the jejunum, which was resected and immunohistochemically verified as GAN-tumor.
  • Several trials of adjuvant chemotherapy (adriamycine/ifosamide, taxotere, gemcitabine/xyloda) were ineffective.
  • Since the first description of the GAN-tumor in 1984 87 patients were reported in the literature.
  • A tumor seize of more than 10 cm is associated with recurrences in 64% of the cases within 2 years.
  • Since there is no option for medical treatment, surgical resection is the treatment of choice and has to be considered also in the case of recurrence.
  • [MeSH-major] Autonomic Nervous System Diseases / surgery. Ileal Neoplasms / surgery. Ileum / innervation. Jejunal Neoplasms / surgery. Jejunum / innervation. Neoplasm Recurrence, Local / surgery. Peripheral Nervous System Neoplasms / surgery
  • [MeSH-minor] Autonomic Nervous System / pathology. Combined Modality Therapy. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Autonomic Nervous System Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11699287.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


3. Plata-Salamán CR: Central nervous system mechanisms contributing to the cachexia-anorexia syndrome. Nutrition; 2000 Oct;16(10):1009-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system mechanisms contributing to the cachexia-anorexia syndrome.
  • Cachexia-anorexia may result from pain, depression or anxiety, hypogeusia and hyposmia, taste and food aversions, chronic nausea, vomiting, early satiety, malfunction of the gastrointestinal system (delayed digestion, malabsorption, gastric stasis and associated delayed emptying, and/or atrophic changes of the mucosa), metabolic shifts, cytokine action, production of substances by tumor cells, and/or iatrogenic causes such as chemotherapy and radiotherapy.
  • The cachexia-anorexia syndrome also involves metabolic and immune changes (mediated by either the pathophysiologic process, i.e., tumor, or host-derived chemical factors, e.g., peptides, neurotransmitters, cytokines, and lipid-mobilizing factors) and is associated with hypertriacylglycerolemia, lipolysis, and acceleration of protein turnover.
  • Cytokines are proposed to participate in the development and/or progression of cachexia-anorexia; interleukin-1, interleukin-6 (and its subfamily members such as ciliary neurotrophic factor and leukemia inhibitory factor), interferon-gamma, tumor necrosis factor-alpha, and brain-derived neurotrophic factor have been associated with various cachectic conditions.
  • Brain synthesis of cytokines has been shown in peripheral models of cancer, peripheral inflammation, and during peripheral cytokine administration; these data support a role for brain cytokines as mediators of neurologic and neuropsychiatric manifestations of disease and in the brain-to-peripheral communication (e.g., through the autonomic nervous system).
  • [MeSH-minor] Chronic Disease. Humans. Time Factors

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11054608.001).
  • [ISSN] 0899-9007
  • [Journal-full-title] Nutrition (Burbank, Los Angeles County, Calif.)
  • [ISO-abbreviation] Nutrition
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Cytokines
  • [Number-of-references] 50
  •  go-up   go-down


Advertisement
4. Nada T, Nomura M, Koshiba K, Kawano T, Mikawa J, Ito S: Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity. Arzneimittelforschung; 2007;57(11):698-704
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity.
  • A dihydropyridine calcium (Ca) antagonist, azelnidipine (CAS 123524-52-7, Calblock), exhibits hypotensive effects for a prolonged duration, and has been reported to have a strong antiarteriosclerotic action due to its high affinity for vascular tissues and antioxidative action.
  • In this study, the antiarteriosclerotic and cardiac hypertrophy-inhibitory effects, and the autonomic nervous activity in essential hypertension of azelnidipine were investigated.
  • 1) Pulse wave velocity (PWV), carotid arterial intima media thickness (IMT), echocardiography, high sensitive C-reactive protein (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), adiponectin, brain natriuretic peptide (BNP), and 8-isoprostane were measured after an initial treatment with azelnidipine.
  • 2) The treatment was switched to azelnidipine in patients who had previously been under treatment with amlodipine for essential hypertension, and 123I-metaiodobenzylguanidine myocardial scintigraphy (123I-MIBG), measurements of plasma norepinephrine, atrial natriuretic peptide (ANP), and BNP, Holter electrocardiography, and heart rate variability analysis were performed.
  • The levels of 8-isoprostane, an antioxidative marker, were also significantly decreased, while adioponectin levels were significantly increased after the initial treatment with azelnidipine.
  • These findings suggest that azelnidipine inhibits the enhancement of sympathetic nervous activity and the progression of arteriosclerosis through its antioxidative effects.
  • [MeSH-major] Antihypertensive Agents / therapeutic use. Azetidinecarboxylic Acid / analogs & derivatives. Calcium Channel Blockers / therapeutic use. Dihydropyridines / therapeutic use. Hypertension / drug therapy
  • [MeSH-minor] 3-Iodobenzylguanidine. Adipokines / metabolism. Aged. Antioxidants / metabolism. Arteriosclerosis / complications. Arteriosclerosis / radionuclide imaging. Autonomic Nervous System / drug effects. Cardiomegaly / etiology. Cardiomegaly / radionuclide imaging. Carotid Arteries / radionuclide imaging. Catecholamines / blood. Cytokines / metabolism. Electrocardiography / drug effects. Female. Heart Rate / drug effects. Humans. Male. Middle Aged. Natriuretic Peptide, Brain / metabolism. Pulse. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Essential hypertension.
  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18193691.001).
  • [ISSN] 0004-4172
  • [Journal-full-title] Arzneimittel-Forschung
  • [ISO-abbreviation] Arzneimittelforschung
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adipokines; 0 / Antihypertensive Agents; 0 / Antioxidants; 0 / Calcium Channel Blockers; 0 / Catecholamines; 0 / Cytokines; 0 / Dihydropyridines; 0 / Radiopharmaceuticals; 114471-18-0 / Natriuretic Peptide, Brain; 2517-04-6 / Azetidinecarboxylic Acid; 35MRW7B4AD / 3-Iodobenzylguanidine; PV23P19YUG / azelnidipine
  •  go-up   go-down


5. Gerstner E, Batchelor T: Primary CNS lymphoma. Expert Rev Anticancer Ther; 2007 May;7(5):689-700
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary CNS lymphoma in immunocompetent patients is associated with unique diagnostic, prognostic and therapeutic issues and the management of this malignancy is different from other forms of extranodal non-Hodgkin's lymphoma.
  • Characteristic imaging features should lead to suspicion of the diagnosis, avoidance of corticosteroids (if possible) and early neurosurgical consultation for stereotactic biopsy.
  • Resection provides no therapeutic benefit and should be reserved for the rare patient with neurological deterioration due to brain herniation.
  • Whole-brain radiation therapy alone is insufficient for durable tumor control and is associated with a high risk of neurotoxicity in patients over 60 years of age.
  • Neurotoxicity is typically associated with significant cognitive, motor and autonomic dysfunction and has a negative impact on quality of life.
  • Chemotherapy and whole-brain radiation therapy together improve tumor response rates and survival compared with whole-brain radiation therapy alone.
  • Methotrexate-based multiagent chemotherapy without whole-brain radiation therapy is associated with similar tumor response rates and survival compared with regimens that include whole-brain radiation therapy, although controlled trials have not been performed.
  • The risk of neurotoxicity is lower in patients treated with chemotherapy alone.
  • The incidence of HIV-related primary CNS lymphoma has decreased in the era of highly active antiretroviral therapy.
  • Patients with HIV-associated primary CNS lymphoma have a worse prognosis but may respond to highly active antiretroviral therapy, whole-brain radiation therapy or therapies directed against the Epstein-Barr virus.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Antiretroviral Therapy, Highly Active. Combined Modality Therapy. HIV Infections / complications. HIV Infections / drug therapy. Humans. Injections, Spinal. Methotrexate / administration & dosage. Prognosis. Radiotherapy / adverse effects. Stem Cell Transplantation

  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Pneumocystosis and HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17492932.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 71
  •  go-up   go-down


6. Batchelor T, Loeffler JS: Primary CNS lymphoma. J Clin Oncol; 2006 Mar 10;24(8):1281-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PCNSL in immunocompetent patients is associated with unique diagnostic, prognostic, and therapeutic issues, and the management of this malignancy is different from that of other forms of extranodal NHL.
  • Characteristic imaging features should be suggestive of the diagnosis, avoidance of corticosteroids, if possible, and early neurosurgical consultation for stereotactic biopsy.
  • Resection provides no therapeutic benefit and should be reserved for the rare patient with neurologic deterioration due to brain herniation.
  • Whole-brain radiation therapy (WBRT) alone is insufficient for durable tumor control and is associated with a high risk of neurotoxicity in patients older than age 60.
  • Neurotoxicity typically is associated with significant cognitive, motor, and autonomic dysfunction, and has a negative impact on quality of life.
  • Chemotherapy and WBRT together improve tumor response rates and survival compared with WBRT alone.
  • Methotrexate-based multiagent chemotherapy without WBRT is associated with similar tumor response rates and survival compared with regimens that include WBRT, although controlled trials have not been performed.
  • The risk of neurotoxicity is lower in patients treated with chemotherapy alone.
  • [MeSH-major] Central Nervous System Neoplasms. Lymphoma, Non-Hodgkin

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16525183.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 51
  •  go-up   go-down


7. Holman AJ, Ng E: Heart rate variability predicts anti-tumor necrosis factor therapy response for inflammatory arthritis. Auton Neurosci; 2008 Dec 5;143(1-2):58-67
Hazardous Substances Data Bank. Etanercept .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heart rate variability predicts anti-tumor necrosis factor therapy response for inflammatory arthritis.
  • To consider autonomic status as a predictor of anti-tumor necrosis factor (TNF) treatment response for inflammatory arthritis, we conducted an exploratory, double-blind, 52-week study with 33 patients with rheumatoid (25) or psoriatic (8) arthritis using heart rate variability (HRV).
  • All were assessed for parasympathetic, sympathetic, total power and tension index measures of autonomic reactivity at initiation of anti-TNF therapy with etanercept (15) or adalimumab (18).
  • Only parasympathetic and tension index predicted DAS28 outcome (p-value range 0.009-0.024).
  • Poor anti-TNF response was associated with low parasympathetic, low total power, high sympathetic and high tension index measures, a profile also predominant in the prior anti-TNF failure subset (12).
  • In conclusion, this unique, exploratory study suggests that HRV may be a novel, useful predictor of response to anti-TNF therapy in patients with inflammatory arthritis, and emphasizes the importance of autonomic influence of autoimmune disease expression.
  • [MeSH-major] Antirheumatic Agents / therapeutic use. Arthritis, Psoriatic / drug therapy. Arthritis, Rheumatoid / drug therapy. Heart Rate / drug effects. Tumor Necrosis Factors / antagonists & inhibitors
  • [MeSH-minor] Adalimumab. Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Autonomic Nervous System / drug effects. Autonomic Nervous System / physiopathology. Double-Blind Method. Etanercept. Female. Humans. Immunoglobulin G / therapeutic use. Male. Middle Aged. Predictive Value of Tests. Receptors, Tumor Necrosis Factor / therapeutic use. Severity of Illness Index. Treatment Outcome

  • Genetic Alliance. consumer health - Heart tumor.
  • Genetic Alliance. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Psoriatic Arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18632310.001).
  • [ISSN] 1872-7484
  • [Journal-full-title] Autonomic neuroscience : basic & clinical
  • [ISO-abbreviation] Auton Neurosci
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antirheumatic Agents; 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factors; FYS6T7F842 / Adalimumab; OP401G7OJC / Etanercept
  •  go-up   go-down


8. Aronson D, Burger AJ: Effect of beta-blockade on autonomic modulation of heart rate and neurohormonal profile in decompensated heart failure. Ann Noninvasive Electrocardiol; 2001 Apr;6(2):98-106
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of beta-blockade on autonomic modulation of heart rate and neurohormonal profile in decompensated heart failure.
  • BACKGROUND: One of the putative mechanisms for the salutary effects of beta-blockers in patients with congestive heart failure (CHF) is their ability to improve autonomic dysfunction.
  • METHODS: Time and frequency domain HRV indices were obtained from 24-hour Holter recordings and compared to assess the role of beta-blockade in 199 patients (mean age 60 +/- 14 years) with decompensated CHF.
  • Neurohormonal differences were assessed by measuring norepinephrine, endothelin-1, tumor necrosis factor-alpha, and interleukin-6 in a subset of 64 patients.
  • Time domain measures of parasympathetic cardiac activity, the percentage of R-R intervals with > 50 ms variation (4.9 +/- 0.6 vs 7.7 +/- 1.2%, P = 0.006) and the square root of mean squared differences of successive R-R intervals (22.7 +/- 2.0 vs 31.6 +/- 4.1 ms, P = 0.004), were higher in the beta-blocker group.
  • CONCLUSIONS: Beta-blockers improve the impaired cardiac autonomic regulation during high sympathetic stress of decompensated CHF.
  • [MeSH-major] Adrenergic beta-Antagonists / therapeutic use. Autonomic Nervous System / drug effects. Endothelin-1 / blood. Endothelin-1 / drug effects. Heart Failure / complications. Heart Failure / drug therapy. Heart Rate / drug effects. Interleukin-6 / blood. Neurotransmitter Agents / blood. Norepinephrine / blood. Tachycardia, Ventricular / etiology. Tachycardia, Ventricular / prevention & control. Tumor Necrosis Factor-alpha / drug effects. Tumor Necrosis Factor-alpha / metabolism
  • [MeSH-minor] Aged. Disease Progression. Electrocardiography, Ambulatory. Female. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • Hazardous Substances Data Bank. Norepinephrine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11333166.001).
  • [ISSN] 1082-720X
  • [Journal-full-title] Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc
  • [ISO-abbreviation] Ann Noninvasive Electrocardiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 0 / Endothelin-1; 0 / Interleukin-6; 0 / Neurotransmitter Agents; 0 / Tumor Necrosis Factor-alpha; X4W3ENH1CV / Norepinephrine
  •  go-up   go-down


9. Kenemans P, Kubista E, Foidart JM, Yip CH, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Beckmann MW, Bundred NJ, Egberts J, van Os S, Planellas J: Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients--design and baseline data 'LIBERATE' trial. Breast; 2007 Dec;16 Suppl 2:S182-9
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients--design and baseline data 'LIBERATE' trial.
  • Many patients with a history of breast cancer (BC) will suffer from vasomotor symptoms, which can be induced or exacerbated by treatment with tamoxifen or aromatase inhibitors.
  • Mean age at randomization was 52.6 years, and the mean time since surgery was 2.1 years.
  • For the primary tumor, Stage IIA or higher was reported for >70% of the patients.
  • Chemotherapy was reported by 5% at randomization.
  • The adjuvant tamoxifen use in LIBERATE allows a comparison with the Stockholm trial (showing no risk of BC recurrence associated with hormone therapy), which was stopped prematurely subsequent to HABITS.
  • The LIBERATE trial is the largest, ongoing, well-controlled study for treatment of vasomotor symptoms in BC patients.
  • [MeSH-major] Antineoplastic Agents, Hormonal / pharmacology. Autonomic Nervous System Diseases / drug therapy. Breast Neoplasms / drug therapy. Norpregnenes / pharmacology. Vasomotor System / drug effects
  • [MeSH-minor] Aromatase Inhibitors / adverse effects. Aromatase Inhibitors / pharmacology. Aromatase Inhibitors / therapeutic use. Bone Density. Double-Blind Method. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Quality of Life. Survival Analysis. Tamoxifen / adverse effects. Tamoxifen / pharmacology. Tamoxifen / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Autonomic Nervous System Disorders.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Breast. 2008 Apr;17(2):214-5. Egberts, J [added]; van Os, S [added]; Planellas, J [added]
  • (PMID = 17983942.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0 / Norpregnenes; 094ZI81Y45 / Tamoxifen; FF9X0205V2 / tibolone
  •  go-up   go-down


10. Shen J, Horii Y, Fujisaki Y, Nagai K: Effects of L-arginine and L-lysine mixtures on splenic sympathetic nerve activity and tumor proliferation. Auton Neurosci; 2009 May 11;147(1-2):86-90
Hazardous Substances Data Bank. (L)-ARGININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of L-arginine and L-lysine mixtures on splenic sympathetic nerve activity and tumor proliferation.
  • Oral supplementations of L-arginine and L-lysine show tumor inhibition abilities.
  • An increase in splenic-SNA and tumor volume (2 mM), no effect (10 mM), and a decrease in both values (50 mM) were seen.
  • Bivariate correlation analysis revealed a positive correlation between changes in splenic-SNA and tumor volume, indicating the tumor suppressing ability of weakened splenic-SNA.
  • [MeSH-major] Arginine / pharmacology. Immune Tolerance / drug effects. Lysine / pharmacology. Neoplasms / drug therapy. Neuroimmunomodulation / drug effects. Sympathetic Nervous System / drug effects
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / immunology. Carcinoma / physiopathology. Cell Proliferation / drug effects. Colonic Neoplasms / drug therapy. Colonic Neoplasms / immunology. Colonic Neoplasms / physiopathology. Disease Models, Animal. Female. Humans. Immunologic Factors / pharmacology. Immunologic Factors / therapeutic use. Killer Cells, Natural / immunology. Male. Mice. Mice, Inbred BALB C. Rats. Rats, Wistar. Spleen / cytology. Spleen / immunology. Spleen / innervation. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. L-Lysine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19237319.001).
  • [ISSN] 1872-7484
  • [Journal-full-title] Autonomic neuroscience : basic & clinical
  • [ISO-abbreviation] Auton Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunologic Factors; 94ZLA3W45F / Arginine; K3Z4F929H6 / Lysine
  •  go-up   go-down


11. Mazur KA: Neuroblastoma: What the nurse practitioner should know. J Am Acad Nurse Pract; 2010 May;22(5):236-45
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To provide a comprehensive review of the background, diagnosis, and primary care management of neuroblastoma (NBL) and to describe the pathophysiology, signs and symptoms, and diagnostic tests for the patient with NBL.
  • CONCLUSIONS: NBL is one of the most common tumors of childhood and clinical presentation depends on the site of the primary tumor as well as the presence and location of any metastasis.
  • Treatment includes a combination of surgery, chemotherapy, and radiation, as well as the newer immunotherapy.
  • The clinical presentation of NBL, the vital facts needed to ensure that this diagnosis will not be overlooked, and follow-up in a primary care setting will be reviewed.
  • [MeSH-minor] Anthracyclines / therapeutic use. Antineoplastic Agents / therapeutic use. Autonomic Nervous System Diseases / diagnosis. Autonomic Nervous System Diseases / nursing. Autonomic Nervous System Diseases / pathology. Immunotherapy. Neural Crest / cytology. Neural Crest / pathology. Prognosis. Radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20500737.001).
  • [ISSN] 1745-7599
  • [Journal-full-title] Journal of the American Academy of Nurse Practitioners
  • [ISO-abbreviation] J Am Acad Nurse Pract
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antineoplastic Agents
  • [Number-of-references] 26
  •  go-up   go-down


12. Krychun II: [Effect of a complex treatment, including glutargin and erbisol on the blood plasma content of protein P53, apoptotic markers of type II, activity of caspases and the level of sCD 117 in patients with autonomic-vascular dystonia]. Lik Sprava; 2008 Apr-Jun;(3-4):49-56
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of a complex treatment, including glutargin and erbisol on the blood plasma content of protein P53, apoptotic markers of type II, activity of caspases and the level of sCD 117 in patients with autonomic-vascular dystonia].
  • It has been established that the blood content of protein P53 diminishes by 27%, the blood level of sTRAIL increases by 22%, sCD 117 increases by 44% in patients with vegeto-vascular dystonia of the hypertonic type that is accompanied by an increase of the activity of caspases-1 however the activity of caspases-3 and - 8 as well as the blood content of TNF-alpha do not change.
  • Multimodality therapy using glutargin does not influence on the level of the blood plasma TNF-alpha and the activity of caspases-1,-3,-8, normalizes the blood content of sTRAIL and sCD 117, however does not change the plasma concentration of protein P53 which remains lower by 35% than the control indices.
  • In patients with vegeto-vascular dystonia of the hypotonic type the concentration of blood plasma protein P53, TNF-alpha and sTRAIL and the activity of caspases-1,-3,-8 correspond to the control values against a background of an almost twofold increase of the plasma sCD 117 level.
  • The use of erbisol in a complex of therapeutic agents does not change the activity of caspases-l,-3,-8 and does not influence on the blood content of protein p53, TNF-alpha and sTRAIL and diminishes the plasma level of sCD 117 up to control values.
  • A considerable elevation of the blood content of type II apoptotic factors is characteristic of the mixed type of vegeto-vascular dystonia: the level of protein p53 increases 2,4 times, TNF-alpha - 1,9 times, sTRAIL - 2,3 times that is accompanied by an increased activity of caspase-1 - 4,1 times, caspase-3 - 3,3 times, caspase-8 - 3,8 times and an increase of the plasma concentration of sCD 117 - 3,5 times.
  • The use of erbisol and glutargin in multimodality therapy normalizes the plasma concentration of TNF-alpha and diminishes the blood content of protein P53 by 33% and sTRAIL - by 42% which, nevertheless remains higher than the control value by 58% and 36% respectively.

  • Genetic Alliance. consumer health - Dystonia.
  • MedlinePlus Health Information. consumer health - Autonomic Nervous System Disorders.
  • MedlinePlus Health Information. consumer health - Vascular Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19145821.001).
  • [ISSN] 1019-5297
  • [Journal-full-title] Likars'ka sprava
  • [ISO-abbreviation] Lik. Sprava
  • [Language] UKR
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Biological Factors; 0 / Biomarkers; 0 / Dipeptides; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Tumor Necrosis Factor-alpha; 0 / Tumor Suppressor Protein p53; 0 / erbisol; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 3.4.22.- / Caspases; TU1X77K34Q / arginine glutamate
  •  go-up   go-down


13. Horenstein MG, Hitchcock TA, Tucker JA: Dual CD117 expression in gastrointestinal stromal tumor (GIST) and paraganglioma of Carney triad: a case report. Int J Surg Pathol; 2005 Jan;13(1):87-92
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dual CD117 expression in gastrointestinal stromal tumor (GIST) and paraganglioma of Carney triad: a case report.
  • We report a 36-year-old white woman with complete Carney triad, including metastatic gastric stromal tumor (GIST), pulmonary chondroma, and nonfunctioning extra-adrenal paraganglioma.
  • To our knowledge, this is the 21st complete Carney triad case reported and the first report of dual expression CD117 in both GIST and paraganglioma, a finding with intriguing pathogenetic implications related to the organization of the autonomic nervous system.
  • [MeSH-major] Chondroma / pathology. Gastrointestinal Stromal Tumors / pathology. Leiomyosarcoma / secondary. Lung Neoplasms / pathology. Paraganglioma, Extra-Adrenal / pathology. Proto-Oncogene Proteins c-kit / analysis
  • [MeSH-minor] Adult. Antigens, CD34 / analysis. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Chromogranins / analysis. Drug Therapy. Female. Humans. Palliative Care. Syndrome

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735861.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Chromogranins; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


14. An MM, Zou Z, Shen H, Liu P, Chen ML, Cao YB, Jiang YY: Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol; 2010 Aug;66(8):813-21
MedlinePlus Health Information. consumer health - High Blood Pressure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to gain a better understanding of the overall incidence and risk of significantly raised blood pressure in cancer patients who receive bevacizumab therapy.
  • Bevacizumab treatment was associated with a statistically significant increased risk of developing significantly raised blood pressure (RR 5.38, 95% CI 3.63-7.97).
  • CONCLUSIONS: Among the patients included in the trials analyzed in this meta-analysis, the addition of bevacizumab to cancer therapy treatments significantly increased the risk of significantly raised blood pressure.
  • The risk may be dose-dependent and vary with tumor type.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Autonomic Nervous System Diseases / epidemiology. Cardiovascular Diseases / epidemiology. Hypertension / chemically induced. Meta-Analysis as Topic. Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Bevacizumab. Breast Neoplasms / chemically induced. Breast Neoplasms / drug therapy. Carcinoma, Renal Cell / chemically induced. Carcinoma, Renal Cell / drug therapy. Female. Humans. Incidence. Randomized Controlled Trials as Topic. Risk Factors. Vascular Endothelial Growth Factor A / therapeutic use

  • MedlinePlus Health Information. consumer health - Autonomic Nervous System Disorders.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):792-9 [15681523.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):671-80 [15705858.001]
  • [Cites] Am J Kidney Dis. 2007 Feb;49(2):186-93 [17261421.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):2013-9 [18421054.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] BMJ. 1994 Nov 19;309(6965):1351-5 [7866085.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4743-50 [17909199.001]
  • [Cites] Lancet Oncol. 2008 Feb;9(2):117-23 [18221915.001]
  • [Cites] Control Clin Trials. 1986 Sep;7(3):177-88 [3802833.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2184-91 [15169807.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3502-8 [15908660.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23 (16):3697-705 [15738537.001]
  • [Cites] Int J Technol Assess Health Care. 1996 Spring;12(2):195-208 [8707495.001]
  • [Cites] N Engl J Med. 2007 Dec 27;357(26):2666-76 [18160686.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1539-44 [17442997.001]
  • [Cites] Lancet. 2007 Dec 22;370(9605):2103-11 [18156031.001]
  • [Cites] Acta Oncol. 2009;48(1):9-17 [18752081.001]
  • [Cites] J Urol. 2008 Sep;180(3):860-5; discussion 865-6 [18635227.001]
  • [Cites] N Engl J Med. 2003 Jul 31;349(5):427-34 [12890841.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1227-34 [19188680.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5422-8 [18936475.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 [12516034.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):60-5 [12506171.001]
  • [Cites] Control Clin Trials. 1996 Feb;17(1):1-12 [8721797.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2231-7 [19307500.001]
  • [Cites] Arch Intern Med. 1996 Mar 25;156(6):661-6 [8629879.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Lancet. 1998 Jan 10;351(9096):123-7 [9439507.001]
  • (PMID = 20401474.001).
  • [ISSN] 1432-1041
  • [Journal-full-title] European journal of clinical pharmacology
  • [ISO-abbreviation] Eur. J. Clin. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


15. Lazzerini PE, Acampa M, Hammoud M, Maffei S, Capecchi PL, Selvi E, Bisogno S, Guideri F, Galeazzi M, Pasini FL: Arrhythmic risk during acute infusion of infliximab: a prospective, single-blind, placebo-controlled, crossover study in patients with chronic arthritis. J Rheumatol; 2008 Oct;35(10):1958-65
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Effects of the drug on measures of arrhythmia risk such as QT interval and heart rate variability (HRV) were evaluated.
  • CONCLUSION: New-onset cardiac arrhythmias, particularly ventricular tachyarrhythmias, developed during IFX infusion, but their incidence did not achieve statistical significance.
  • The acute effects of IFX on autonomic balance may substantiate the role of the complex interaction between autonomic nervous system and inflammation during chronic arthritis.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antirheumatic Agents / adverse effects. Arthritis, Rheumatoid / drug therapy. Tachycardia / chemically induced. Tumor Necrosis Factor-alpha / antagonists & inhibitors

  • Genetic Alliance. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18709695.001).
  • [ISSN] 0315-162X
  • [Journal-full-title] The Journal of rheumatology
  • [ISO-abbreviation] J. Rheumatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antirheumatic Agents; 0 / Placebos; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab
  •  go-up   go-down


16. Likasitwattanakul S: Serotonin syndrome: a case report. J Med Assoc Thai; 2005 Jul;88(7):993-6
Hazardous Substances Data Bank. SERTRALINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serotonin syndrome is a rare but potentially fatal complication of drugs that have effects on central nervous system serotonin.
  • It is characterized by sudden onset of altered mental status, increased neuromuscular activity and autonomic instability.
  • The author reports a child with suprasellar region tumor who presented with depression and obsessive-compulsive disorder and received a combination of sertaline (selective serotonin reuptake inhibitor) and clomipramine (tricyclic antidepressant).
  • The patient's symptoms resolved rapidly with discontinuation of the offending drugs and supportive care.
  • [MeSH-major] Depressive Disorder / drug therapy. Obsessive-Compulsive Disorder / drug therapy. Serotonin Syndrome / diagnosis. Serotonin Uptake Inhibitors / adverse effects. Sertraline / adverse effects

  • Genetic Alliance. consumer health - Serotonin Syndrome.
  • MedlinePlus Health Information. consumer health - Obsessive-Compulsive Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16241032.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Serotonin Uptake Inhibitors; QUC7NX6WMB / Sertraline
  •  go-up   go-down


17. Kirby S, Purdy RA: Headache and brain tumors. Curr Neurol Neurosci Rep; 2007 Mar;7(2):110-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The epidemiology of this clinically relevant area is highlighted along with general clinical features of headache disorders seen in brain tumor patients.
  • Some rarer clinical presentations are noted, particularly in relationship to the newly described trigeminal autonomic cephalalgias, as well as the relationships of headache to pituitary tumors and paroxysmal and positional headaches.
  • Headaches as a result of brain tumor therapy are noted, as is the important area of treatment of headaches in patients with central nervous system neoplasms of a primary or secondary nature.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Brain Neoplasms / complications. Brain Neoplasms / drug therapy. Headache / chemically induced. Headache / etiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Headache.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cephalalgia. 2004 Mar;24(3):173-84 [15009010.001]
  • [Cites] Brain. 1997 Jan;120 ( Pt 1):193-209 [9055807.001]
  • [Cites] Cephalalgia. 2003 Sep;23(7):558-60 [12950384.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1093-112 [7677836.001]
  • [Cites] Cephalalgia. 1994 Aug;14(4):270-2 [7954755.001]
  • [Cites] Cephalalgia. 2004 Dec;24(12):1088-9 [15566423.001]
  • [Cites] Bull N Y Acad Med. 1942 Jun;18(6):400-22 [19312276.001]
  • [Cites] Headache. 1998 Nov-Dec;38(10):782-6 [11279904.001]
  • [Cites] Arch Neurol. 2004 May;61(5):721-5 [15148150.001]
  • [Cites] Headache. 1962 Oct;2:147-52 [14495354.001]
  • [Cites] Brain. 2005 Aug;128(Pt 8):1921-30 [15888539.001]
  • [Cites] Cephalalgia. 2003 Jun;23(5):395-7 [12780771.001]
  • [Cites] Neurology. 2002 Jun 11;58(11):1698-9 [12058109.001]
  • [Cites] Neurosurgery. 1995 Aug;37(2):319-21; discussion 321-2 [7477785.001]
  • [Cites] Headache. 1994 Jul-Aug;34(7):435-8 [7928329.001]
  • [Cites] Neuro Oncol. 2000 Oct;2(4):221-8 [11265231.001]
  • [Cites] J Clin Endocrinol Metab. 2000 May;85(5):1789-93 [10843153.001]
  • [Cites] J Neurooncol. 1991 Feb;10(1):31-46 [2022972.001]
  • [Cites] Headache. 2005 May;45(5):604-6 [15953282.001]
  • [Cites] Eur J Neurol. 2003 Mar;10 (2):169-73 [12603293.001]
  • [Cites] Headache. 2002 Feb;42(2):142-6 [12005291.001]
  • [Cites] Cephalalgia. 2005 Feb;25(2):154-6 [15658954.001]
  • [Cites] Cephalalgia. 2003 Mar;23(2):124-8 [12603369.001]
  • [Cites] Surg Neurol. 2006 Apr;65(4):332-41, discussion 341-2 [16531188.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):364-9 [10470808.001]
  • [Cites] Headache. 2003 May;43(5):499-504 [12752757.001]
  • [Cites] Cephalalgia. 2006 Oct;26(10):1238-41 [16961793.001]
  • [Cites] Anaesthesia. 2005 Jul;60(7):693-704 [15960721.001]
  • [Cites] J Neurosurg. 2006 Jun;104(6):884-91 [16776331.001]
  • [Cites] J Neurosurg. 2002 Jun;96(6):1041-5 [12066904.001]
  • [Cites] J Cancer Res Clin Oncol. 1998;124(5):265-9 [9645457.001]
  • [Cites] Cephalalgia. 2005 Sep;25(9):743-5 [16109057.001]
  • [Cites] Otolaryngol Head Neck Surg. 1992 Sep;107(3):424-9 [1408229.001]
  • [Cites] Cephalalgia. 2004 Mar;24(3):223-7 [15009016.001]
  • [Cites] Neurology. 1981 May;31(5):530-7 [6972014.001]
  • [Cites] Childs Nerv Syst. 1989 Oct;5(5):307-9 [2805001.001]
  • [Cites] Headache. 2001 Jul-Aug;41(7):723-5 [11554962.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Jan;6(1):1-9 [6154024.001]
  • [Cites] Cephalalgia. 1999 Nov;19(9):787-90; discussion 765 [10595287.001]
  • [Cites] Cephalalgia. 2006 Jun;26(6):738-41 [16686914.001]
  • [Cites] Pituitary. 2004;7(3):157-163 [16010459.001]
  • [Cites] Arch Neurol. 1998 Jul;55(7):922-8 [9678309.001]
  • [Cites] Surg Neurol. 2002 May;57(5):295-302; discussion 302-4 [12128295.001]
  • [Cites] Cephalalgia. 2005 Aug;25(8):633-5 [16033391.001]
  • [Cites] Neurology. 2003 Jun 24;60(12):2012-3 [12821758.001]
  • [Cites] Neurology. 1993 Sep;43(9):1678-83 [8414011.001]
  • [Cites] Eur J Cancer Care (Engl). 2006 Mar;15(1):90-5 [16441682.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2063-8 [11932910.001]
  • [Cites] Ann Neurol. 1992 Mar;31(3):268-73 [1637135.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):158-66 [10623706.001]
  • [Cites] Arch Dis Child. 2006 Jun;91(6):502-6 [16547083.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1205-6 [15258238.001]
  • [Cites] Neurosurgery. 2000 Sep;47(3):633-6 [10981750.001]
  • [Cites] Headache. 2003 Mar;43(3):276-8 [12603648.001]
  • [Cites] Pediatrics. 2006 Jun;117(6):e1179-86 [16740818.001]
  • [Cites] Clin Genet. 2004 Nov;66(5):473-5 [15479194.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):224-6 [12134920.001]
  • [Cites] Neurology. 2006 Apr 11;66(7):1105-7 [16606929.001]
  • (PMID = 17324360.001).
  • [ISSN] 1528-4042
  • [Journal-full-title] Current neurology and neuroscience reports
  • [ISO-abbreviation] Curr Neurol Neurosci Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 62
  •  go-up   go-down


18. Aronson D, Mittleman MA, Burger AJ: Interleukin-6 levels are inversely correlated with heart rate variability in patients with decompensated heart failure. J Cardiovasc Electrophysiol; 2001 Mar;12(3):294-300
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because cytokines are known to act at the neuronal level in both the peripheral and central nervous system, we sought to determine whether increased cytokine levels are associated with the autonomic dysfunction that characterizes CHF.
  • Autonomic function was assessed using time- and frequency-domain heart rate variability (HRV) measures, obtained from 24-hour Holter recordings.
  • In addition, norepinephrine, tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) were measured in all patients.
  • IL-6 inversely correlated with the time-domain parameters of standard deviation of RR intervals (SDNN) (r = -0.36, P = 0.004) and standard deviation of all 5-minute mean RR intervals (SDANN) (r = -0.39, P = 0.001), and with the frequency-domain parameters of total power (TP) (r = -0.37, P = 0.003) and ultralow-frequency (ULF) power (r = -0.43, P = 0.001).
  • Using multiple linear regression models, adjusting for clinical variables and drug therapies, the strong inverse relationship between IL-6 and SDNN (P = 0.006), SDANN (P = 0.001), TP (P = 0.04), and ULF power (P = 0.0007) persisted.

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cardiovasc Electrophysiol. 2001 Mar;12(3):301-2 [11291802.001]
  • (PMID = 11291801.001).
  • [ISSN] 1045-3873
  • [Journal-full-title] Journal of cardiovascular electrophysiology
  • [ISO-abbreviation] J. Cardiovasc. Electrophysiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-6
  •  go-up   go-down


19. Ferrari TC, Moreira PR, Cunha AS: Clinical characterization of neuroschistosomiasis due to Schistosoma mansoni and its treatment. Acta Trop; 2008 Nov-Dec;108(2-3):89-97

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characterization of neuroschistosomiasis due to Schistosoma mansoni and its treatment.
  • The involvement of the central nervous system (CNS) by Schistosoma mansoni may or may not cause clinical manifestations.
  • Lower limbs pain, weakness and sensory disturbance, and autonomic dysfunctions, particularly bladder dysfunction, are often present.
  • Cerebral NSM presents as a slow-expanding intracranial tumor-like lesion.
  • The diagnosis of spinal cord NSM is based on clinical evidence whereas the cerebral disease is usually diagnosed by biopsy of the nervous tissue.
  • There is no consensus on the treatment of NSM.
  • We discuss the literature data on this topic, and suggest a therapeutic approach based on our experience with 69 spinal cord NSM patients who have been followed up by a long period of time.
  • Outcome is largely dependent on early treatment, particularly in the medullar disorder, and is better in cerebral NSM.
  • [MeSH-major] Neuroschistosomiasis / drug therapy. Neuroschistosomiasis / physiopathology. Schistosomiasis mansoni / drug therapy. Schistosomiasis mansoni / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18499080.001).
  • [ISSN] 1873-6254
  • [Journal-full-title] Acta tropica
  • [ISO-abbreviation] Acta Trop.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 55
  •  go-up   go-down






Advertisement